C4 Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CCCC, updated each market day.
CCCC AI Sentiment
AI sees no strong directional signal for C4 Therapeutics, Inc. stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Sector
Exchange
Market Cap
$420,130,839
Cap Tier
Employees
104
Headquarters
WATERTOWN, MA
Listed Since
Oct. 2, 2020
Website
CCCC Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CCCC Volatility
C4 Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
